A study published in Science Advances has found that combining low doses of DNMT and EZH2 inhibitors can be more effective in treating colorectal cancers and other solid tumors than either drug alone. The research, led by Van Andel Institute scientists, showed that the two medications work together to sensitize cancer cells to treatment. This discovery has paved the way for a Phase I clinical trial to test this combination therapy in patients with colorectal cancer. The study highlights the potential of combination cancer therapies and the importance of targeting epigenetic processes in cancer treatment. The upcoming trial will be supported by the Van Andel Institute–Stand Up To Cancer© (SU2C) Epigenetics Dream Team and a National Cancer Institute Specialized Programs of Research Excellence (SPORE) award.
Source link
Drug combination could hold new promise for treating colorectal cancers and other solid tumors
